STX17 and neoplasm: The results revealed that STX17-DT overexpression was sufficient to confer tumor resistance to axitinib, leading to increased tumor sizes, heavier weights, and higher Ki-67 expression compared with those in the control group when treated with axitinib in vivo (Fig. 3L–O).